Our results suggest that Egr3 may act both as a diagnostic marker (increased expression in cancer compared to normal) and as a prognostic marker that may distinguish between aggressive and non-aggressive tumors (differentially expressed in non-relapse and relapse). Here, EGR3 is linked to cancer.